What is Iterum Therapeutics PLC (ITRM) stock price today?

Iterum Therapeutics PLC (ITRM) currently trades at $0.03 per share. The stock has a market capitalization of $3.75M and a P/E ratio of —x.

Is ITRM stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Iterum Therapeutics PLC has a Smart Value Score of 23/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Iterum Therapeutics PLC's revenue and earnings?

Iterum Therapeutics PLC has trailing twelve-month (TTM) revenue of $390000.00 with profit margins of 0.00%. Earnings per share (EPS) is $-0.72.

ITRM

Iterum Therapeutics PLC

NASDAQ: ITRM · HEALTHCARE · BIOTECHNOLOGY

$0.03

+0.00% today

Updated 2026-04-29

Market cap

$3.75M

P/E ratio

—

P/S ratio

9.62x

EPS (TTM)

$-0.72

Dividend yield

—

52W range

$0 – $1

Volume

32.7M

Market cap

$3.75M

P/E ratio

—

P/S ratio

9.62x

EPS (TTM)

$-0.72

Dividend yield

—

52W range

$0 – $1

Volume

32.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →204 stocks currently score above 75

Price targets

Analyst target

$9.00

+29900.00%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-7.86M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2021	2022	2023	2024	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$390000.00
Net income	$-91.56M	$-44.43M	$-38.37M	$-24.77M	$-8.98M
EPS	—	—	—	—	$-0.72
Free cash flow	$-15.90M	$-18.54M	$-39.34M	$-26.77M	$-7.86M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ITRM	$3.75M	23	3.7	2.5	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Iterum Therapeutics PLC trades at $0.03. Our Smart Value Score of 23/100 indicates the stock is weak. TTM revenue stands at $390000.00.

Frequently asked questions

What is Iterum Therapeutics PLC's stock price?

Iterum Therapeutics PLC (ITRM) trades at $0.03.

Is Iterum Therapeutics PLC overvalued?

Smart Value Score 23/100 (Grade F, Strong Sell).

What is the price target of Iterum Therapeutics PLC (ITRM)?

The analyst target price is $9.00, representing +29900.0% upside from the current price of $0.03.

What is Iterum Therapeutics PLC's revenue?

TTM revenue is $390000.00.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio9.62x

ROE-556.00%

Beta3.01

50D MA$0.26

200D MA$0.59

Shares out0.05B

Float0.05B

Short ratio—

Avg volume32.7M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

ITRM vs LLY →ITRM vs JNJ →ITRM vs ABBV →Stock screener →